R&D channel feed – Endpoints News

R&D channel feed

Another TIGIT trial fails as BeiGene scraps Phase 3 drug

3 months ago

Novartis’ Chinook-originated kidney disease drug gets accelerated approval

3 months ago

Sarepta, Roche pause Elevidys trials in Europe following patient death

3 months ago

Edgewise's heart drug shows promise in Phase 2 trial

3 months ago

Axsome reports Phase 3 depression fail for Sunosi

3 months ago

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed

3 months ago

Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial

3 months ago

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

3 months ago

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

3 months ago

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

3 months ago

Tenaya to lay off about one-third of staff, reveals heart gene therapy data

3 months ago

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

3 months ago

Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer

3 months ago

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

3 months ago

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

3 months ago

Marks’ exit at FDA rattles an already teetering biotech industry

3 months ago

Lilly's heart disease drug could be dosed as little as once a year, study shows

3 months ago

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

3 months ago

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

3 months ago

Vertex’s second-generation diabetes cell therapy fails early-stage study

3 months ago

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

3 months ago

Lykos’ interim CEO is set to step down

3 months ago

Bluebird gets new M&A bid, seeking to top private equity offer

3 months ago

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

3 months ago

First page Previous page 8 9 101112 13 14 Next page Last page